Trump and Kennedy Launch New Initiative to Address Autism from the White House
Andrew Joseph reports on health, medicine, and the biopharma sector in Europe. Connect with Andrew on Signal at drewqjoseph.45.
Daniel Payne analyzes the intersection of health industry dynamics and Washington policies. He joined STAT in 2025 after a tenure at POLITICO covering health care. Reach Daniel on Signal at danielp.100.
In an unprecedented move, the Food and Drug Administration has reapproved a medication that has not been available for over 25 years. This decision aligns with the Trump administration’s initiative to identify potential causes and treatments for autism.
The recently reapproved drug, GSK’s Wellcovorin, is a branded formulation of leucovorin, a widely used generic medication generally prescribed to alleviate side effects associated with certain cancer treatments.
During a dedicated autism event at the White House, President Trump and Health Secretary Robert F. Kennedy Jr. revealed that their administration is investigating the use of leucovorin as a possible therapy for autism. They also highlighted concerns regarding the use of Tylenol during pregnancy, which they suggest may be linked to autism.
-
Andrew Joseph reports on health, medicine, and biopharma in Europe. Connect with Andrew via Signal at drewqjoseph.45.
-
Daniel Payne analyzes the interplay between the health industry and Washington. He joined STAT in 2025 after covering health care at POLITICO. Reach Daniel via Signal at danielp.100.
This rewritten article retains the essential structure and key details of the original while ensuring uniqueness for integration into a WordPress platform.
